Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

357 results
Display

Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

Lim SM, Hong MH, Kim HR

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma

Kim T, Cha YJ, Chang YS

BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is tested by immunohistochemistry (IHC)—22C3, SP263, and SP142. The aim of this study is to evaluate the correlation among the three methods of PD-L1...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Park EY, Kim YS, Choi KH, Song JH, Lee HC, Hong SH, Kang JH

PURPOSE: This study aimed to investigate neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors in patients with locally advanced non-small cell lung cancer (NSCLC) who received concurrent chemoradiotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Local ablative radiotherapy for oligometastatic non-small cell lung cancer

Suh YG, Cho J

In metastatic non-small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been limited to palliation to alleviate the symptoms. However, with the development of advanced RT techniques, recent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS

BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Preoperative Risk Factors for Pathologic N2 Metastasis in Positron Emission Tomography-Computed Tomography–Diagnosed N0–1 Non-Small Cell Lung Cancer

Yoon TH, Lee CH, Park KS, Bae CH, Cho JW, Jang JS

BACKGROUND: Accurate mediastinal lymph node staging is vital for the optimal therapy and prognostication of patients with lung cancer. This study aimed to determine the preoperative risk factors for pN2...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Meta-Analysis Comparing Lobectomy versus Segmentectomy in Stage I Non-Small Cell Lung Cancer

Lim TY, Park S, Kang CH

Lobectomy is considered the standard strategy for early-stage non-small cell lung cancer (NSCLC). However, sublobar resection for NSCLC has recently received increased attention. The objective of this study was to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association between Expression of 8-OHdG and Cigarette Smoking in Non-small Cell Lung Cancer

An AR, Kim KM, Park HS, Jang KY, Moon WS, Kang MJ, Lee YC, Kim JH, Chae HJ, Chung MJ

BACKGROUND: Exposure to cigarette smoking (CS) is a major risk factor for the development of lung cancer. CS is known to cause oxidative DNA damage and mutation of tumor-related genes,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future

Kim H, Chung JH

Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

Shin J, Chung JH, Kim SH, Lee KS, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS

PURPOSE: Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study

Chung E, Noh JM, Lee KC, Kim JH, Chung WK, Suh YG, Lee JA, Seol KH, Wu HG, Kim YS, Noh OK, Park JW, Lee DS, Lee J, Kim YS, Park WY, Kang MK, Jo S, Ahn YC

PURPOSE: Lung Cancer Subcommittee of Korean Radiation Oncology Group (KROG) has recently launched a prospective clinical trial (KROG 17-06) of hippocampus-sparing whole brain radiotherapy (HS-WBRT) with simultaneous integrated boost (SIB)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS

PURPOSE: Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Factors in Stage IIB Non-Small Cell Lung Cancer according to the 8th Edition of TNM Staging System

Shin JW, Cho DG, Choi SY, Park JK, Lee KY, Moon Y

BACKGROUND: The purposes of this study were to evaluate the appropriateness of the stage migration of stage IIA non-small cell lung cancer (NSCLC) in the seventh edition of the tumor,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer

Hong MH, Kim HR, Ahn BC, Heo SJ, Kim JH, Cho BC

PURPOSE: Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (EGFR) mutation testing (e.g., for T790M mutations), and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Morphologic Evaluation of Primary Non-Small Cell Lung Cancer by 3 Tesla MRI with Free-Breathing Ultrashort Echo Time and Radial T1-Weighted Gradient Echo Sequences: A Comparison with CT Analysis

Lee H, Choi E, Lee MK, Zhang Y, Kwon W

PURPOSE: To evaluate morphologic features of primary non-small cell lung cancer using 3 Tesla MRI with free-breathing compared with CT. MATERIALS AND METHODS: Thirty-six patients were enrolled. A 64-channel multidetector CT...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC

PURPOSE: Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer

Lee KH, Ahn YC, Pyo H, Noh JM, Park SG, Kim TG, Lee E, Nam H, Lee H, Sun JM, Ahn JS, Ahn MJ, Park K

PURPOSE: This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer. MATERIALS...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, Sun JM, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ

PURPOSE: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM

PURPOSE: We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC),...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lymph Node Metastasis after Spontaneous Regression of Non-Small Cell Lung Cancer

Jeong JH, Choi PJ, Yi JH, Jeong SS, Lee KN

Spontaneous regression of lung cancer is a very rare and poorly understood phenomenon. A 64-year-old man presented to Dong-A University Hospital with a shrunken nodule in the right lower lobe....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr